Division/Committee: [MEDI: Division of Medicinal Chemistry]

Targeted protein degradation (TPD), which leverages the innate ubiquitin-proteasome system (UPS) using heterobifunctional small molecules (such as PROTACs and molecular glues), has gained significant momentum in biopharma and academia for intractable targets. The goal of this session is to highlight emerging technologies that enable and accelerate progress within the field. The topics to be covered include: DEL screening to accelerate discovery of proximity-inducing small molecules; proximity labeling proteomics to help understand the mechanism of action and to facilitate the rational design of molecular glues; design of covalent-based degraders; development of new CRBN binders; enriching the pool of E3 ligases for targeted protein degradation; and degrader-antibody conjugates as a rising novel modality. The proposed symposium will feature six presentations by speakers from diverse backgrounds, including biotechnology/pharmaceuticals and academic institutions, discussing various strategies for discovering and developing heterobifunctional molecules for TPD. Additionally, this session will explore the challenges of rational chemical design in the context of event-driven pharmacology involved in TPD.

Xingyu Jiang

Genentech Inc

Appearances